Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 1998

View Archived Issues

Techniclone advancing development of Tumor Necrosis Therapy into phase II

PEG-hirudin more effective than heparin in patients with acute coronary syndromes

Hemosol blood substitute to enter phase II clinical trials in U.S. for CABG

AEterna isolates molecule exhibiting anti-MMP activity

Positive results reported from clinical trial of Remune

SNAP-8719: a valuable tool for studying alpha1D-adrenoceptor function

Xoma: Q2 1998 highlights

Medarex receives milestone payment from Merck KGaA

Novartis announces VALIANT trial

CAT demonstrates value of ProxiMol technology

AnorMED initiates phase I clinical trial of AMD-3100

Betaseron to receive fast track review in Canada

Lamotrigine approved for new indication in the U.S.: Lennox-Gastaut syndrome

Cambridge NeuroScience announces advances in MS program

AutoImmune: Q2 1998 highlights

P&U to market Glyset in U.S., Canada and several other countries

Phase I/II trial provides evidence of potential efficacy of ovarian cancer vaccine

Potent new antimalarial trioxanes developed at Johns Hopkins

L-168721: potent, nonpeptide GH secretagogue

Novartis describes search for potent and selective CDK1/CDK2 inhibitors

Lead candidate for botulinum neurotoxin poisoning: ICD-1578

Banyu presents urea derivatives with NPY receptor-antagonist activity

Inhibitors of NOS developed at Pfizer

Anticonvulsant benzamides prepared at SKB

Zeneca patents new peptides for autoimmune/inflammatory disorders

Merck & Co. claims glucagon antagonists, cytokine inhibitors

Compounds interacting with nicotinic receptors for cognitive and memory deficits

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...